RFL PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

RFL ▲ +46.21% at T+60d

NEUTRAL call ✓ call won +46.21% · α vs SPY +36.35% · entry $1.32 → $1.93

Currently $2.24 · +69.70% from $1.32 entry

Entry anchored
Mar 16, 03:58 PM ET
via Databento tick

T+1d

-3.03%

call -3.03% · α -1.63%

$1.28

settled 3mo ago

T+5d

-6.06%

call -6.06% · α -3.41%

$1.24

settled 3mo ago

T+20d

-7.58%

call -7.58% · α -11.88%

$1.22

settled 2mo ago

T+60d

+46.21%

call +46.21% · α +36.35%

$1.93

settled 3d ago

Price Chart

Loading chart...

Executive Summary

Rafael Holdings reported Q2 FY2026 financial results with a net loss of $6.4 million, wider than the prior year's $4.6 million loss, driven by increased R&D expenses from the Cyclo Therapeutics acquisition. Despite higher losses, cash remains strong at $37.8 million, and the company continues to advance its pivotal Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1, with top-line results expected in Q3 2026.

Key Financial Metrics

Revenue

$211.0K

+174.0% YoY

EPS

$-0.13

Actionable Insight

Traders should monitor upcoming top-line Phase 3 data in Q3 2026 as the primary catalyst; current losses are expected due to trial costs, but a positive readout could significantly revalue the stock given the unmet medical need in NPC1.

Key Facts

Net loss for Q2 FY2026 was $6.4 million ($0.13/share), up from $4.6 million ($0.19/share) in the year-ago period.
R&D expenses rose to $4.5 million from $0.9 million due to consolidation of Cyclo Therapeutics post-acquisition in March 2025.
Cash and cash equivalents were $37.8 million as of January 31, 2026, down from $52.8 million at the start of the fiscal year.
Pivotal Phase 3 TransportNPC™ trial for Trappsol® Cyclo™ remains on track, with top-line results expected in Q3 2026.
Total revenue increased to $211K from $77K, primarily due to new product revenue of $125K.

Financial Impact

Increased R&D spend added ~$3.6M in costs; product revenue contributed $125K. Net loss widened by $1.8M YoY.

net lossr_d_expenserevenuecash

Risk Factors

Clinical trial failure risk for Trappsol® Cyclo™ in Phase 3 could lead to sharp downside.
Continued cash burn may necessitate future dilution if no near-term commercial path or partnership emerges.

Market Snapshot

Exchange

NYSE

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3256686

5 reports for RFL

T+1T+5T+20T+60

Filters

Reports for RFL — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	8-K MIXED ★ 7/10	$1.82 awaiting T+20	awaiting T+20	—	$2.24 (+23.42%)
Jun 10, 2026 3d ago	8-K NEUTRAL ★ 5/10	$1.90 awaiting T+20	awaiting T+20	—	$2.24 (+17.89%)
Jun 10, 2026 3d ago	Press Release BULLISH ★ 7/10	$1.90 awaiting T+20	awaiting T+20	—	$2.24 (+17.89%)
Apr 22, 2026 7w ago	8-K NEUTRAL ★ 4/10	$1.30 $1.35	▲ +3.85%	▲ +0.68%	$2.24 (+72.31%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$1.32 $1.22	▼ −7.58%	▼ −11.88%	$2.24 (+69.70%)

US Market Status

Market Closed — Opens Mon (49h 37m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access